What Do Analysts Think Of Mainz Biomed N.V (MYNZ)

Mainz Biomed N.V (MYNZ) saw an uptrend of 7.03% in the recent trading with $1.98 being its most recent. The current price level -89.58% lower than the highest price of $19.00 marked by the stock while trading over the past 52-weeks, whereas it is 47.97% higher than the lowest price of $1.34 the company dropped to over past 52-weeks. The latest news story on MYNZ appeared in (GlobeNewswire) under the title “Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition” on Today.

Do analysts rate it as a buy, sell or hold?

Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.

Mainz Biomed N.V Earnings – What Happened With MYNZ

Coming around sales and income figures on MYNZ Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.

Mainz Biomed N.V – Insider Activity and Holdings

Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 3.81 million. MYNZ does have institutional investors; and they hold 6.13% of the stock.

As on 2024-06-30, NORTHERN TRUST CORP was the top most holder in Mainz Biomed N.V (NASDAQ:MYNZ) with an ownership of 29934.0 shares of the company or 0.1414 of the stake worth $12004.0. The filing also reveals VONTOBEL HOLDING LTD. as the second largest holder in the company with a control over 0.1181 of the outstanding shares. Its stake is worth $10025.0 for having 25000.0 shares in hand.

GEODE CAPITAL MANAGEMENT, LLC also came holding a key position in the company during the recent quarter and it now holds 0.0718 of the outstanding shares. With this there are now 12.0 institutions which have possession in MYNZ’s shares.

Key Metrics forMYNZ

Technical Analysis of Mainz Biomed N.V (NASDAQ:MYNZ) stock

To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Mainz Biomed N.V (MYNZ), we notice that the stock’s 20-day average volume is at 213,325 shares and 50% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 50% are spotting the stock at Sell with its 50-day average volume of 146,808 shares. And to end, MYNZ’s 100-day average volume is 183,866 shares with 100% of the long-term indicators pointing towards Sell for the stock.

The Baxter Report
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.